Aptinyx 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Craig Jalbert

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	1.9yrs

최근 관리 업데이트

Recent updates

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

Jan 30

Aptinyx recommences Phase 2 study of NYX-2925

Jan 04

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

Dec 26

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 27

CEO

Craig Jalbert (61 yo)

less than a year

테뉴어

Mr. Craig R. Jalbert, CIRA, serves as President, Corporate Secretary, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at Evelo Biosciences, Inc. since November 21,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Craig Jalbert	Principal Executive Officer	less than a year	데이터 없음	데이터 없음
Patrick Flavin	Senior Manager of Corporate Development & Investor Relations	no data	데이터 없음	데이터 없음
Molly Dir	Vice President of Human Resources	2.6yrs	데이터 없음	데이터 없음
Kathryn King	Senior Vice President of Clinical & CMC Operations	5yrs	데이터 없음	데이터 없음
Tim Noffke	VP of Program Management & Chief of Staff	1.7yrs	데이터 없음	데이터 없음
Harald Murck	Vice President of Clinical & Medical Affairs	3yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

경험이 풍부한 관리: APTX 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Craig Jalbert	Principal Executive Officer	less than a year	데이터 없음	데이터 없음
Peter LeWitt	Member of Scientific Advisory Board	1.9yrs	데이터 없음	데이터 없음
Gerard Sanacora	Member of Scientific Advisory Board	1.9yrs	데이터 없음	데이터 없음
Lesley Arnold	Member of Scientific Advisory Board	1.9yrs	데이터 없음	데이터 없음
Chadi Abdallah	Member of Scientific Advisory Board	1.9yrs	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

경험이 풍부한 이사회: APTX 의 이사회는 경험(평균 재직 기간 1.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Aptinyx 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Aptinyx Inc. Announces Chief Executive Officer Changes

Aptinyx Inc. Announces Executive Changes

Aptinyx Inc. Announces Resignation of Patrick Enright from Board of Directors

High number of new directors

High number of new directors

Aptinyx Inc., Annual General Meeting, May 26, 2022

Recent updates

Aptinyx Inc. Approves Liquidating Cash Distribution

Nasdaq to Delist the Common Stock of Aptinyx

Aptinyx Inc. Announces Chief Executive Officer Changes

Aptinyx Inc. is Heading Towards Bankruptcy

Aptinyx Inc. announced delayed 10-Q filing

The Nasdaq Stock Market LLC Notifies Aptinyx Regarding Non-Compliance with Certain Board and Committee Composition Listing Requirements

Aptinyx Inc. Announces Executive Changes

Aptinyx Receives Non-Compliance Notice from Nasdaq

Aptinyx Inc. Announces Resignation of Patrick Enright from Board of Directors

Price target decreased to US$2.27

High number of new directors

Aptinyx Inc. to Report Q3, 2022 Results on Nov 08, 2022

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Aptinyx Inc. Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

Aptinyx Inc. Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD At the 2022 American Psychiatric Association Annual Meeting

Price target decreased to US$5.33

Aptinyx Inc. Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting

High number of new directors

Price target decreased to US$6.50

Aptinyx Inc. Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with Nyx-783

Aptinyx Inc Announces Temporarily Paused the Initiation of its Phase 2b Study of the 150 mg Dose of NYX-783 in Patients with Post-Traumatic Stress Disorder

Aptinyx Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$7.71

Aptinyx Inc. Reports Results from Phase 2B Study of Nyx-2925 in Painful Diabetic Peripheral Neuropathy

Consensus forecasts updated

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

Aptinyx Inc. Announces Formation of Scientific Advisory Board

High number of new directors

Independent Director recently bought US$50k worth of stock

Aptinyx Initiates Phase 2B Study of NYX-783 in Patients with Post-Traumatic Stress Disorder

CFO & Chief Business Officer recently bought US$102k worth of stock

Independent Director recently bought US$192k worth of stock

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.24 loss in 3Q 2020)

High number of new directors

We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate

Consensus forecasts updated

Aptinyx: CNS Drug Discoverer With Depressed Price

Aptinyx Inc.(NasdaqGS:APTX) dropped from Russell 3000E Value Index

Aptinyx Inc. Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder

Aptinyx updates on mid-stage clinical program for PTSD therapy

First quarter 2021 earnings released: US$0.21 loss per share (vs US$0.34 loss in 1Q 2020)

Aptinyx Inc. Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD At Society of Biological Psychiatry Annual Meeting

Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans

Full year 2020 earnings released: US$1.02 loss per share (vs US$1.71 loss in FY 2019)

Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?

New 90-day low: US$3.20

Aptinyx Inc. to Report Q4, 2020 Results on Mar 24, 2021

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

New 90-day high: US$4.33

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients with Painful Diabetic Peripheral Neuropathy

Aptinyx recommences Phase 2 study of NYX-2925

Aptinyx Appoints Andy Kidd as President and COO

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

Aptinyx Inc. Appoints Andy Kidd, M.D. as President and Chief Operating Officer

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Analysts update estimates

Analysts update estimates

Price target lowered to US$10.50

Aptinyx Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$2.98

Aptinyx Reports Positive, Statistically Significant, Top-Line Data from Phase 2 Study of Nyx-783 in Patients with Post-Traumatic Stress Disorder

Aptinyx Inc. Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia

New 90-day low - US$3.48

Analysts update estimates

First half earnings released

Aptinyx Inc. to Report Q2, 2020 Results on Aug 13, 2020

CEO

테뉴어